Metabolic evidence map
Tirzepatide vs Cagrilintide–Semaglutide
A cross-program evidence map comparing dual GIP/GLP-1 agonism with coadministered amylin/GLP-1 agonism. This is not a head-to-head efficacy verdict.
Editorial answer
The short answer
Both programs have Phase 3 evidence, but the key obesity percentages come from different trials. CagriSema trials evaluate a sponsor-controlled coadministration and cannot validate a third-party blend.
Research and evidence interpretation only. No usage or dosing guidance.Structured comparison
Compare like with like
Every difference includes an interpretation note so a molecular or protocol distinction is not converted into a marketing claim.
Swipe horizontally to compare every column
| Question | Tirzepatide | Cagrilintide–Semaglutide | Editorial interpretation |
|---|---|---|---|
| Design | Single peptide with GIP and GLP-1 receptor agonism | Coadministration of long-acting amylin analogue cagrilintide and GLP-1 agonist semaglutide | A coformulated or coadministered drug program is not equivalent to an unspecified blend. |
| Key obesity study | SURMOUNT-1; Phase 3; 2,539 adults without diabetes; 72 weeks | REDEFINE 1; Phase 3a; 3,417 adults without diabetes; 68 weeks | Separate protocols and estimands prevent a causal cross-trial comparison. |
| Mean body-weight result | −15.0%, −19.5% and −20.9% across three dose groups; placebo −3.1% | −20.4% with coadministration; placebo −3.0% | Numerical proximity does not establish equivalence or superiority. |
| Type 2 diabetes evidence | Multiple tirzepatide development and approved-product studies | REDEFINE 2 reported −13.7% versus −3.4% placebo at 68 weeks | Populations and background therapies must remain attached to results. |
| U.S. status | Tirzepatide is used in FDA-approved finished medicines | The cited studies evaluate an investigational combination program | Catalog materials are not the regulated finished products. |
Evidence cards
What the linked records actually report
Findings remain attached to the study population, experimental model and source type.
Tirzepatide produced dose-specific mean weight changes over 72 weeks in adults without diabetes.
The study did not include CagriSema.Open source ↗Cagrilintide–semaglutide produced a −20.4% estimated mean change at week 68 versus −3.0% with placebo.
The active-controlled semaglutide and cagrilintide arms do not create a direct tirzepatide comparison.Open source ↗In adults with type 2 diabetes, the combination produced −13.7% versus −3.4% with placebo at week 68.
This population differs from both SURMOUNT-1 and REDEFINE 1.Open source ↗Translation boundary
What this comparison cannot establish
- That one program is superior based on separate trial percentages.
- That a catalog Cagrilintide + Semaglutide blend is CagriSema.
- That approved tirzepatide labeling applies to research powder.
Sources
References used for this comparison
- 01Phase 3 RCT
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, et al. N Engl J Med. 2022;387:205–216. PMID 35658024.
- 02Phase 3a RCT
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
N Engl J Med. 2025. PMID 40544433.
- 03Phase 3a RCT
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
N Engl J Med. 2025. PMID 40544432.
- 04FDA record
ZEPBOUND (tirzepatide) prescribing information
U.S. FDA. Revised 2026. NDA 217806.
Editorial analysis
Read the product-specific source reviews
These articles expand individual identity, trial and evidence questions without changing the comparison conclusions above.
Tirzepatide Dual GIP/GLP-1 Signaling: Mechanism and Trial Endpoints Explained
An evidence-led explanation of tirzepatide dual receptor agonism and the endpoints measured in SURPASS and SURMOUNT trials, with clear limits on applying drug data…
Read source review →Tirzepatide in 2026: Approved Drug Evidence vs Research-Use Material
Why an FDA-approved tirzepatide medicine, a compounded product and a research-use catalog material are not interchangeable evidence categories.
Read source review →Cagrilintide vs CagriSema: Molecules, Trial Evidence and Common Mix-Ups
A clean comparison of cagrilintide, semaglutide and the studied CagriSema combination, including 2025–2026 phase 3 records and limits on transferring evidence.
Read source review →Comparison FAQ
Questions this page is designed to answer
Was CagriSema compared directly with tirzepatide?
No direct randomized comparison was identified in the core trials summarized here.
Can REDEFINE results be used for a catalog blend?
No. The trials used sponsor-controlled interventions with defined manufacturing, formulation and clinical monitoring.
Continue researching